Kornimate/medical-research-clean huggingface dataset:
single anastomosis sleeve ileal bypass versus single anastomosis sleeve jejunal bypass

Conditions: Obesity, Morbid

Summary: to compare the results of sasi to sas-j in treatment of morbid obesity

200 of patients indicated for obesity surgery will be divided into 2 groups : group 1, will be operated by sasi and group 2, will be operated by sas-j

Eligibility criteria:
inclusion criteria: * obese patients with bmi more than 40 with or without co-morbidity or more than 35 with co-morbidity * patients fit for laparoscopic surgery * give approval to share in the study exclusion criteria: * patients refused to share in the study * patients unfit for surgery * patients aged less than 18 and older than 60 * patient with previous upper abdominal surgery either for obesity or other diseases * revisional bariatric procedures
apixaban drug utilization study in stroke prevention in atrial fibrillation (spaf)

Conditions: Atrial Fibrillation

Summary: apixaban is a direct anticoagulant, which inhibits the factor xa. its clinical efficiency in prevention of stroke and systemic embolism in adult patients with nvaf (non/valvular atrial fibrillation) was demonstrated as well as has shown better safety profile compared with warfarin. a drug utilization study will evaluate whether this drug has been used in accordance with the approved indication and recommendations described in the summary of product characteristics (smpc) and estimate possible misuse or overuse apixaban.

the primary research question is to evaluate the apixaban utilization according to the approved spaf indication and recommendations by ema. in addition a comparison with a cohort of nvaf patients treated with vka, dabigatran and rivaroxaban for the spaf indication will also be performed. objective 1: to characterize patients using apixaban according to demographics, comorbidity, risk of thromboembolic events (chads2 and cha2ds2-vasc scores), risk of bleeding events (has-bled score), comedications and compare it with the profile of patients treated with vka, dabigatran and rivaroxaban. objective 2: describe the level of appropriate usage according to the posology recommended in the apixaban smpc. objective 3: describe the potential interactions with other drugs prescribed concomintatly according with the smpc recommendations. objective 4: estimate the level of apixaban adherence by the medication possession ratio (mpr) and discontinuation rates and compare it with vka, dabigatran and rivaroxaban cohort. objective 5: to analyze inr (international normalized ratio) values during the last 12 months and to obtain ttr (time in therapeutic range) values in patients previously treated with vka, and during the whole study period for those in the cohort treated with vka.

Eligibility criteria:
inclusion criteria: 1. patients more than 18 years-old. 2. patients diagnosed with nvaf registered in primary care according to icd-10. 3. patients initiating apixaban (naïve or vka experienced), vka (naïve or vka experienced), dabigatran or rivaroxaban for the spaf indication. 4. continuous enrolment in the 12 months pre-index. exclusion criteria: 1. patients with valvular heart disease (icd 10: i05.0-i05.09, i08.0-i08.9) including patients with mitral prosthetic valves. 2. lost to follow-up (e.g. transfer to primary care center non-ics).

Keywords: atrial fibrillation apixaban stroke
the effects of the drugs used in hypotensive anaesthesia on cochlea

Conditions: Anesthesia; Adverse Effect; Reflex, Abnormal; Tinnitus, Spontaneous Oto-Acoustic Emission

Summary: the aim of this study is to find the effects of anesthetics used in hypotensive anesthesia on stapes reflex and distortion product auto acoustic emission.

this study was aimed at evaluating the effects of dexmedetomidine and esmolol on stapes reflex and distortion product auto acoustic emission. the stapes reflex and auto acoustic emission are of considerable diagnostic significances in otolaryngology this are objective methods for the assessment of auditory function.

Eligibility criteria:
inclusion criteria: * 18-65 age * american society of anaesthesiologists physical status classification (asa)1-2 * tympanoplasty surgery * patients with normal stapes reflexes exclusion criteria: * hypertension * drug allergy * cardiac problems * pregnancy

Keywords: dexmedetomidine esmolol stapes reflex
lateral neck lymph node mapping in thyroid cancer

Conditions: Thyroid Cancer

Summary: this study includes papillary thyroid cancer patients who have unpalpable lateral neck lymph nodes but suspicious on ultrasound and/or ct. carbon nanoparticles is used as the tracer for lateral neck lymph node mapping.


Eligibility criteria:
inclusion criteria: * newly diagnosed papillary thyroid cancer * the maximum diameter of the thyroid cancer \<3 cm with enough normal thyroid tissue for tracer injection * unpalpable lateral neck lymph nodes * ultrasound and ct showed suspected lateral neck lymph nodes \<2 cm exclusion criteria: * previously treated thyroid cancer * high risk thyroid cancer (e.g. with severe extra-adenial invasion or extensive lymph node metastasis or poorly differentiated thyroid cancer) * patients with distant metastasis

Keywords: thyroid cancer lateral neck lymph node lymph node mapping neck dissection sentinel lymph node
kegel exercise pregnant training mhealth app

Conditions: Pregnancy Related; Urinary Incontinence

Summary: this pilot feasibility study protocol is to assess the feasibility in the future definitive trial that is the kegel exercise pregnancy training app (kept-app) trial. the aim of this study as follows: (1) to evaluate the recruitment capability of the pregnant women, (2) to evaluate the acceptability of the kept-app, (3) to determine the implementation feasibility of using kept-app, and (4) to determine the preliminary effectiveness of kept-app to improve pfmt skills of pregnant women.

the aim of this pilot feasibility study as follows: (1) to evaluate the recruitment capability of the pregnant women, (2) to evaluate the acceptability of the kept-app, (3) to determine the implementation feasibility of using kept-app, and (4) to determine the preliminary effectiveness of kept-app to improve pfmt skills of pregnant women.

Eligibility criteria:
inclusion criteria: * pregnant women at 26-27 weeks of gestation, any parity with either stress ui or mixed ui will be included. * participants are malaysian citizens who consist of malay, chinese, indian, and native ethnicities. exclusion criteria: * pregnant women with a chronic medical problem(s) before pregnancy, complicated pregnancies or conditions which are not advisable to practise pfmt will be excluded.

Keywords: pilot study feasibility study acceptability mhealth app pelvic floor muscle training
ridge preservation comparing the healing with or without a barrier membrane

Conditions: Jaw, Edentulous, Partially

Summary: ridge preservation comparing the clinical and histologic healing of membrane vs. no membrane approach to grafting.

thirty patients will be treated using the principles of bone grafting for ridge preservation. fifteen test patients will receive a flap technique with an intrasocket cancellous cortical particulate allograft plus a facial overlay graft using a bovine xenograft without a membrane where only the exposed intrasocket allograft will be covered with a piece of alloderm gbr. the positive control group of fifteen patients will receive a flap technique with an intrasocket cancellous cortical particulate allograft plus a facial overlay graft using a bovine xenograft plus alloderm gbr membrane. approximately, four months post-surgery, a trephine core will be taken from the grafted site immediately prior to implant placement and submitted for histologic processing.

Eligibility criteria:
inclusion criteria: 1. have one non-molar tooth requiring extraction that will be replaced by a dental implant. the site must be bordered by at least one tooth. 2. healthy male or female who is at least 18 years old. 3. patients must sign an informed consent approved by the university of louisville human studies committee. exclusion criteria: 1. patients with debilitating systemic diseases, or diseases that have a clinically significant effect on the periodontium. 2. presence or history of osteonecrosis of jaws. 3. patients who are currently taking iv bisphosphonates or who had iv treatment with bisphosphonates irrespective of duration. 4. patients who have been treated with oral bisphosphonates for more than three years. 5. patients with an allergy to any material or medication used in the study. 6. patients who need prophylactic antibiotics 7. previous head and neck radiation therapy. 8. chemotherapy in the previous 12 months. 9. patients on long term nsaid or steroid therapy. 10. pregnant patients.

Keywords: regeneration bone regeneration grafting, bone allograft xenograft
a study to evaluate safety, tolerability, pharmacokinetics and pharmacology of ono-4474 in healthy volunteers

Conditions: Osteoarthritis

Summary: a phase 1 study to evaluate safety, tolerability, pharmacokinetics and pharmacology of ono-4474 in healthy volunteers.

a double-blind, multi-centre, single dose, single and multiple ascending dose, four-part, randomised, placebo-controlled study in healthy adult and elderly subjects exploring the safety, tolerability, pharmacokinetics of ono-4474 in fed and fasted conditions, and pharmacology of ono-4474 in ngf-hyperalgesia.

Eligibility criteria:
inclusion criteria: 1. healthy male subjects aged 18-55 years inclusive (parts a and c); healthy male and female subjects aged 18-55 years inclusive (part b); healthy male and female subjects aged 65 and over (part d) 2. subjects with a body mass index of 18.0-30.0 kg/m2 inclusive exclusion criteria: 1. subjects who have a clinically relevant history or presence of any clinically significant disease or disorder 2. current smokers or those that have smoked or used nicotine products within 6 months of the screening visit
patient characteristics and treatment modalities in copd patients in china

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: chronic obstructive pulmonary disease (copd) is a complex disease characterized by multiple clinical manifestations as well as co-morbidities. while copd subjects have traditionally been classified based solely on airflow limitation (forced expiratory volume in one second \[fev1\]), a new classification system was introduced in the year of 2011 by the global initiative for chronic obstructive lung disease (gold) that recommended subjects with copd should be classified based on a combination of airflow limitation, disease impact (determined by symptom burden and activity limitation) and history of exacerbation. this approach results in the classification of subjects in four groups: a (low risk, less symptoms), b (low risk, more symptoms), c (high risk, less symptoms), and d (high risk, more symptoms). this classification system was further refined in year 2013, specifically around the history of exacerbation definition, where having ≥1 exacerbation leading to hospital admission in preceding year was added as a criteria for classification into the "high risk" c or d groups. further, in the year 2016, there was a refinement of the disease impact criteria that suggest the use of the copd assessment test (cat) score (over the modified british medical research council dyspnea scale \[mmrc\] score) as the preferred tool to determine classification as "more symptoms" or "less symptoms". this study aims to understand subject characteristics and current treatment modalities in different groups classified by gold 2016 comprehensive classification system and to understand if current treatment choice is concordant with the gold recommendations in real life clinical practice in china tertiary hospitals. it will provide a useful point-in-time description of copd subject characteristics and current treatment modalities in real life clinical practice in china.


Eligibility criteria:
inclusion criteria * aged 40 years and older * a clinical diagnosis of copd for at least one year: dyspnea, chronic cough or sputum production, and a history of exposure to risk factors for the disease and lung function test fev1/ fvc \<0.7(post bronchodilator) * out-patient * able to read, comprehend, and record information in chinese * a signed and dated written informed consent must be obtained from the subject prior to study participation exclusion criteria * current exacerbation or an exacerbation within the preceding one month * other unstable diseases which could influence cat and lung function results (judged by physicians) * a medical diagnosis of active tuberculosis, cystic fibrosis, any other pulmonary condition, lung cancer, or hypereosinophilic syndromes (hes) * currently participating in another copd clinical study which provides the subject investigational medication and/or disease management

Keywords: fev1 copd cat treatment modality fvc gold 2016 mmrc
safety and pharmacokinetics of orally administered gallium maltolate in various refractory malignancies

Conditions: Prostatic Neoplasms; Multiple Myeloma; Bladder Neoplasms; Lymphoma

Summary: this study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment. this dosing cycle will be repeated. adverse effects will be assessed and the levels of gallium in serum will be measured. any effect of the drug on the cancer and any improvement in cancer-related symptoms will also be measured.

gallium maltolate is an orally bioavailable form of gallium. this is a safety, pharmacokinetic and preliminary efficacy study. the primary objective of the study is to assess the safety profile in patients after oral administration of different doses of gallium maltolate for up to six 42-day cycles (28 days of gallium maltolate, followed by 14 days off treatment). in addition, serum concentrations of gallium and associated pharmacokinetic variables will be measured. from this information, an optimal dose will be selected for assessment of anti-tumor efficacy. the study assesses the effects of oral administration of gallium maltolate on pain resulting from bony metastasis, on biochemical measures of bone turnover, and on disease progression and overall survival in patients with various refractory malignancies. patients may receive up to 6 cycles of the investigational agent.

Eligibility criteria:
inclusion criteria: * patients with hormone refractory prostate cancer, refractory multiple myeloma, refractory bladder cancer, or malignant lymphoma; * life expectancy of ≥6 months, * zubrod performance status of ≤2, * adequate bone marrow function, renal function, liver function and pulmonary function; * age ≥ 18 years; * willing and able to give informed consent; and * effective contraceptive use or non child-bearing potential. exclusion criteria: * 10% weight loss in the previous 3 months; * active serious infection not controlled by antibiotics; * initiation of bisphosphonates treatment within 30 days; * participation in other research study within 30 days; * uncontrolled brain metastasis, * prior intrathecal chemotherapy or whole-brain radiotherapy, * inability to comply with protocol or undergo specified tests; * other active malignancy; * optic neuritis, and * routine use of diuretics (for initial phase of study only).
flips: ferfer liposomal iron performance study

Conditions: Iron Deficiency Anemia

Summary: to evaluate the efficacy of a novel food supplement, ferfer® to raise the capacity of haemoglobin and haematocrit levels

anemia, described as a low blood haemoglobin concentration, has been shown to be a public health problem that impacts low-, center- and high-earnings nations and has great unfavorable health results, as well as unfavorable influences on social and monetary development . even though the most dependable indicator of anemia on the populace stage is blood haemoglobin attention, measurements of this attention by myself do now not determine the cause of anemia. anemia may additionally result from a number of causes, with the maximum great contributor being iron deficiency. approximately 30%- 50% of instances of anemia are taken into consideration to be because of iron deficiency. doctor will evaluate on the basis of inclusion or exclusion criteria, lab values and overall assessment and then enroll in this clinical trial. during the study patient will visit the doctor four times, day 0 week 4, week 8 and week 12. doctor will investigate the hemoglobin level and hematocrit level and also evaluate the adverse effects and tolerability of ferfer® at week 2 and week 8. doctor also instructed to take the food supplements, twice daily, once in a morning and once in evening independently by food intake as ferfer® has no interaction with food.

Eligibility criteria:
inclusion criteria: * iron deficiency anemia (hemoglobin \ 5 g/dl) * subjects able to provide written informed consent; * subjects already treated with other iron supplements or drugs that experienced side effects (not including allergy) related to iron administration. * wash out period will be a week exclusion criteria: * had a history of iron intolerance * hypersensitivity and allergic of vit c and vit b12 * not willing to take informed consent

Keywords: ida iron deficiency anemia iron supplements pakistan liposomal iron
delayed puberty in boys; clinical and biochemical characteristics and effect of testosterone treatment

Conditions: Delayed Puberty

Summary: to evaluate the phenotype and biochemical characteristics of boys referred for delayed puberty, to describe the frequency of associated co-morbidities and diseases, to evaluate the diagnostic criteria and the effect of testosterone treatment.

delayed puberty in boys; clinical and biochemical characteristics and effect of testosterone treatment, is a retrospective study in a large case series of danish boys with delayed puberty. all boys were referred to the department of growth and reproduction to be evaluated for delayed puberty. medical history: birth length, birth weight, gestational age at birth, medical history (including cryptorchidism and hypospadias), family history of delayed puberty in mother, father and possible siblings. physical examination: pubertal staging according to tanners classification of boys, genitalia development (g1-g5), pubic hair development (ph1-ph6), axillary hair (yes/no), axillary sweat (yes/no), gynecomastia (yes/no), micropenis (yes/no), height, mother height, father height, target height, weight, bmi, bone age and predicted adult height. blood sampling for measurement of hormone levels: follicle stimulating hormone (fsh), luteinizing hormone (lh), estradiol, anti-mullerian hormone, sex hormone-binding globulin, testosterone, dehydroepiandrosterone-sulfate, androstenedione, inhibin a, inhibin b, growth hormone, insulin like growth factor-1 and insulin like growth factor binding protein-3. gonadotropin-releasing hormone stimulation test for measurement of peak fsh and peak lh. retrospective dna analysis looking for common polymorphisms. if testosterone treatment were initiated, route of administration, dose and duration of treatment were registered.

Eligibility criteria:
inclusion criteria: * all boys identified in the period from january 1990 to february 2013 exclusion criteria: * misclassified (other diagnoses) * insufficient data * lost to follow up

Keywords: delayed puberty boys hormones polymorphism, genetic
association of acne vulgaris with oral hygiene and gingivitis

Conditions: Acne Vulgaris; Gingivitis; Dental Plaque; Oral Hygiene; Puberty

Summary: the goal of this observational study is to learn about in the relationship between acne vulgaris and oral hygiene and gingivitis. the main questions it aims to answer are: * is there a relationship between the severity of acne vulgaris lesions and the severity of plaque-related gingivitis? * could oral hygiene or the severity of plaque-related gingivitis have an impact on the treatment of acne lesions? participants will; * first be examined at the dermatology clinic. * then be examined at the periodontology clinic. * participants with severe acne vulgaris lesions will be examined a second time at the dermatology clinic. (1.5 months after the first examination) * regularly use the antibiotic containing 100 mg doxycycline prescribed in the dermatology clinic for acne treatment. (patients deemed suitable by the dermatologist)


Eligibility criteria:
inclusion criteria: * being systemically healthy * not using any medication regularly * not having received acne treatment before * not having a known allergy to doxycycline/tetracycline antibiotics * not having received periodontal disease treatment in the last 6 months * not having taken antibiotics or anti-inflammatory drugs in the last month * not having used antiseptic mouthwash in the last month * being between the ages of 13-18 * no radiographic bone loss or clinical attachment loss * absence of any diagnosed psychiatric disease exclusion criteria: * smoking * using antibiotics and anti-inflammatory drugs * having significant psychological problems * mouth breathing
a pilot trial of disposable nitrous oxide canisters in providing pain control during burn dressing changes

Conditions: Burns; Pain, Acute

Summary: improvements in burn care have resulted in increased survival. despite these improved outcomes one of the leading challenges of burn care remains providing adequate analgesia during routine wound care and dressing changes. the traditional use of narcotics is challenging as the therapeutic window between analgesia and suppression of breathing becomes narrow with the intense pain and high doses of narcotics needed for dressing changes.

the normal challenges of using narcotics are increased in burn patients, who have significantly altered metabolism. unfortunately, the use of regular general anesthesia or conscious sedation is not a viable option due to the resources required, and as the hypermetabolism of burn injury would result in compromised wound healing with repeated periods of without eating related halting of nutritional intake. this has led to the use of a number of adjuncts ranging from nonmedical (virtual reality, mindfulness, hypnosis etc.) to medication (ketamine, anxiolytics etc.). historically nitrous oxide has been used in similar settings where severe procedural pain is of relatively shorter duration, such as tooth extraction, labor or minor surgical procedures. nitrous oxide is a rapidly acting analgesic that takes effect seconds after inhalation, and lasts minutes. while a randomized trial of nitrous oxide in burn care has been proposed, the only published information currently available is in a chinese medical journal. to address this a gap in knowledge, a pilot randomized controlled trial is proposed to evaluate if nitrous oxide in the form of limited dose inhaler canisters can be used to improve pain control during burn dressing changes compared to placebo canisters.

Eligibility criteria:
inclusion criteria * adult burn patients admitted to the health sciences centre * total body surface area burned of 5-20% exclusion criteria * admitted to intensive care unit * unable to participate in the measurement outcomes (sedated, cognitively impaired, unable to understand english or visually impaired) * medical condition that precludes using nitrous oxide (respiratory disease and significant cardiovascular disease 5). * pregnant * physically unable to hold the canister * \<90% sao2 on room air * face burn * pre-injury narcotics (relative exclusion) * use of iv ketamine * pre-existing lung injury

Keywords: burns, pain, dressing change, nitrous oxide